Jasbir Seehra - Jun 9, 2022 Form 4 Insider Report for Keros Therapeutics, Inc. (KROS)

Role
Chief Executive Officer, Director
Signature
/s/ Keith Regnante, Attorney-in-Fact
Stock symbol
KROS
Transactions as of
Jun 9, 2022
Transactions value $
$1,500
Form type
4
Date filed
6/10/2022, 04:12 PM
Previous filing
Jan 25, 2022
Next filing
Jun 17, 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KROS Common Stock Options Exercise $1.5K +5K +2.05% $0.30* 249K Jun 9, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KROS Employee Stock Option (right to buy) Options Exercise $0 -5K -36.17% $0.00 8.82K Jun 9, 2022 Common Stock 5K $0.30 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Fully vested and exercisable.